Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
09:52
627K+ volume
$.073 price
Guess they like the news
Sorry
09:54
$.0739
10%+ increase
Morning Wick,
It was/is.
This PR just confirms that Sigma Labs is fulfilling it's mandate of what it originally set out to do.
New processes (3d metal printing adoption) takes time and the time is starting to come to fruition. The company is moving towards their stated goals. Albeit, a little slower than we (as investors) hoped, but moving forward non the less.
Good news all around - except for one or two people.
NEW NEWS!!!!
REMEMBER THE PHRASE - "INTEL INSIDE?" WE"VE GOT SIGMA INSIDE!!!!
From Chris.
Sigma Labs Announces OEM Partner Program
SANTA FE, N.M. – September 17, 2015 – Sigma Labs, Inc. (OTCQB: SGLB) (“Sigma Labs” or the “Company”), a developer of advanced, in process, non-destructive quality inspection systems for metal-based additive manufacturing (“AM”) and other advanced manufacturing technologies, today announced that it has launched an “OEM Partner Program” to expedite the trial and incorporation of the Company’s PrintRite3D® quality assurance software into AM machines worldwide. Working closely with Original Equipment Manufacturers (OEMs) remains an important element of Sigma Labs’ growth strategy, with the goal of having the Company’s software embedded in machines before they are sold to end users. The OEM Partner Program includes pricing incentives for bundled software, training, and marketing support; participating companies will be able to provide third party, independent quality assurance via Sigma Labs’ complete suite of PrintRite3D® software modules – INSPECT™, DEFORM™ and ANALYTICS™ – to their customers when machines are purchased. The Company is already in active discussions with several OEMs regarding such partnership opportunities.
“This OEM Partner Program, like our Early Adopter Program, is designed specifically to expedite trial and usage of our PrintRite3D® software for in process quality assurance during 3D printing,” said Mark Cola, President and CEO of Sigma Labs. “Working directly with OEMs will increase the adoption of our systems and provide important feedback for application development in real-world scenarios. We look forward to partnering with some of the globe’s AM machine and software technology leaders to advance an understanding of our software and broaden awareness of the Company in general. We expect to have a number of manufacturers licensing our systems for deployment in the very near future.”
About Sigma Labs, Inc.
Sigma Labs, Inc., through its wholly-owned subsidiary B6 Sigma, Inc., develops and engineers advanced, in-process, non-destructive quality inspection systems for commercial firms worldwide seeking productive solutions for metal-based additive manufacturing or 3D printing, and other advanced manufacturing technologies. For more information please visit www.sigmalabsinc.com.
Looks like shorting - and yes shorting happens on the OTC all the time. A lot of big dumps executed. Also some tree shaking going on.
Just my opinion.
Yup, some short'n and shaking going on today.
Thank's Rookie.
Morning Kanya,
That's how Day traders/shorter's work. Gota get that McDonalds lunch money somehow. Just remember where it's coming from.
B-chart still has avxt as a 100% buy.
Rookie, can you put up a screenshot of the bid/ask/MM's?
Sorry, My Bad!
I guess someone wants really cheap shares. Good luck with that.:)))))))))
WOW!!!
Has anyone else noticed an inverse of the Bid/Ask????
Just noticed bid at.03 and ask at.029.
Bwahahahahahaha!!!
So do I!
Still a 100% buy rating for AVXT!!!!!!!!!!!
I think a couple of shorts are getting out - maybe before more good news comes out?
Just my opinion
"NEWS"
Sigma Labs and Additive Industries Enter Evaluation Period for PrintRite3D®
SANTA FE, N.M. – September 11, 2015 – Sigma Labs, Inc. (OTCQB: SGLB) (“Sigma Labs” or the “Company”), a developer of advanced, in process, non-destructive quality inspection systems for metal-based additive manufacturing (“AM”) and other advanced manufacturing technologies, today announced that it has entered into an evaluation period for the Company’s proprietary PrintRite3D® products with Additive Industries of The Netherlands. As part of the agreement, Additive Industries has purchased a non-exclusive license to use one of Sigma Labs' PrintRite3D® systems – including licensing of its INSPECT™, DEFORM™ and ANALYTICS™ software – to be integrated into a MetalFAB1 prototype machine for evaluation purposes. As previously announced, the two companies signed a Technology Cooperation Agreement in December, 2014 to evaluate Sigma Labs’ technology for Additive Industries’ system development.
Additive Industries is developing next-generation metal AM machines that address the demanding applications of high-end industrial markets. The company has developed and tested a prototype machine to the point where it can now begin to evaluate Sigma Labs' PrintRite3D® technology prior to the product launch of Additive Industries’ MetalFAB1 machine in the fourth quarter of 2015.
“Sigma Labs is delighted by this next stage of development with Additive Industries,” said Mark Cola, President and CEO of Sigma Labs. “The fact that our PrintRite3D® technology is being recognized not just by users of metal AM machines but also by the OEMs that make them is a significant achievement. Machine manufacturers are beginning to understand the value of offering their customers an enabling technology to assure the quality and reliability of metal AM products. We are pleased to join with Additive Industries in their product launch later this year.”
“I am excited that we are now able to capitalize on our partnership, which points to the rapidly-evolving industrial AM space as well as increased end-user demand,” said Daan Kersten, Co-founder & CEO of Additive Industries b.v. “This evaluation period is the next logical step in the co-development project between Sigma Labs and Additive Industries, as well as a natural bridge in our joint efforts to improve the reliability and consistency of metal AM machines.”
About Sigma Labs, Inc.
Sigma Labs, Inc., through its wholly-owned subsidiary B6 Sigma, Inc., develops and engineers advanced, in-process, non-destructive quality inspection systems for commercial firms worldwide seeking productive solutions for metal-based additive manufacturing or 3D printing, and other advanced manufacturing technologies. For more information please visit www.sigmalabsinc.com.
About Additive Industries B.V.
Additive Industries is dedicated to bringing metal additive manufacturing for functional parts from lab to fab by offering a modular 3D printing system and seamlessly integrated information platform to high-end and demanding industrial markets. With substantially improved reproducibility, productivity, and flexibility, Additive Industries redefines the business case for additive manufacturing applications in aerospace, automotive, medical technology and high-tech equipment. Additional information can be found at www.additiveindustries.com.
Went over to B A R C H A R T .
In their Snapshot opinion they NOW have AVXT in the "TOP 1%" for BOTH strength and direction.
GLTA
Relax Ten,
There many old sayings or clichés.
"Any port in a storm","it's always darkest before the dawn", etc.
As far as the OTC is concerned I'll go with.... "Any up day ..... is a good day."
If someone wants to buy 50K or 70K at the ask it shows that at least someone is showing an interest in AVXT. Would I like volume at 1M+, sure. But if you look at the past year, there were days/weeks on end with volume at 0. You couldn't give this stock away and the price showed it.
AVXT has turned a new page in their book. Whether things work out - who knows.
I do know I'll take .026 over sub penny any day.
What I do know from the PR is that CTCA and AVAX have settled, Firebird has taken preferred shares over cash debt (yea, just another form), the FDA has given them the go ahead for phase III trials for Melanoma (once they have raised the money for the trial). So it is looking better. I'm sure other shareholders that purchased at higher dollar amounts and hung on are happier as well.
AND, I am sure that folks that are facing the scourge of melanoma are happy that there may be even a small ray of hope for a treatment.
Good luck to you.
Getting interesting now!
Impressive, 51K slap at .026
Spread is real tight.
Ohooooo, Baby!!!
Barchart has AVXT as a **** 100% BUY*
"Snapshot opinion" rates AVXT in the top 1% for direction and 100 for strength!!!!!!
Time for GGG to put out financials or be relegated to stinky pinky status. Talk is cheap. Put out a quarterly report at the end of the next quarter.
Nice volume already!
Barchart has AVXT as an - 88% "strong buy"
FYI
Hmmm. lets see. Trader (shorter)sells 20K at avg. price of .01655 - 2 x 10K trades .0166 & .0165.
.0175-.01655=.00095
20K x .00095=$19
Wonderful. Now he/she can go out to McDonalds for supper tonight!
What a moron.
Someone trying to hold the lid on this thing????
Exactly!!!!!!!!
Oxymoron?
"...provide "us" the shareholders.........(.0001)soon "hopefully" before next month.
Should get rid of the "OXY" part.
I think gold's trying to say we should be into triple digits ($100+/share) soon.:):)
Nice volume today
Held out quite well considering the world Stock exchanges today
Faired OK - considering the absolute beat down on the world stock exchanges today.
Sorry - made an error
Numbers not correct.
They are working on financing. They are going to start registering patients later this year. Phase III trial will begin once financing is secured. PR states a company from Canada is working on getting private placements for financing. FDA approval has been aquired for M-Vax phase III testing.
Please re-read the PR and check out info on their website.
Pair of good size buys at end of day. .014 close
From the web site.
"AVAX is developing a proprietary Autologous Cell (AC) Vaccine® Platform, a therapy that stimulates a patient’s immune system to combat his/her own (autologous) tumor-specific cancer cells,
containing the most relevant antigens by use of whole tumor. AVAX’s MVax®, with an orphan drug designation, is positioned, pending financing, to enter a Phase III pivotal registration clinical trial for Stage IV melanoma approved by the FDA. The Company has also completed a Phase I/II clinical trial for ovarian cancer, using its OVax® vaccine at Cancer Treatment Centers of America (“CTCA”). Results from this trial have demonstrated survival rates and a sustained reduction of CA-125 levels that far surpass expectations for patients of this disease stage. Due to the dearth of Ovarian Cancer treatments and potentially additional evidence supporting ,the MVAX trial findings, AVAX believes results from a new, well-designed Phase IIb study in Ovarian could be a major value driver for the company. AVAX has been “dark” since 2008 due to financing concerns, but is seeking to re-list on a major exchange, under a reconstituted management team upon or contemporaneous with obtaining additional financing."
Notice the PHASE III M-Vax trial has been approved already by the FDA. Sounds like they just need the financing.
Hope they put out a BIG, FAT, PR when they get it!
Someone asked a few posts back - issued shares number. (common shares)
Best I could find (and I could be wrong) was from 2008 - approx. 141,500,000 shares outstanding - with 500,000,000 authorized.
Hope this helps.
Yes it was. Now the trick is to keep it up to date with relevant info. Once they get FDA approval to begin stage 3 trials for O-Vax or M-Vax - a PR is a must necessity.
I think they need to put out a PR as soon as possible.
Thank's Bayetta.
A few highlights from the website.
MVax® for the Treatment of Melanoma
AVAX's Phase III Study
AVAX plans to launch an International Phase III Registration trial with its lead product MVax® by the end of the year. The Phase III study will enroll approximately 400 patients. AVAX has met with the United States Food and Drug Administration ("FDA") on the study design and has plans to continue to work with FDA to be able to focus and re-launch this pivotal clinical study.
The protocol will be based on published data showing that administration of MVax® alone can induce clinically meaningful anti-tumor responses in patients with stage III and IV melanoma.